Adamas Announces Declaratory Judgment Action Filed by Osmotica Related to Approved OSMOLEX ER
Adamas Pharmaceuticals, Inc. (ADMS)
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adamaspharma.com/investors
Company Research
Source: GlobeNewswire
EMERYVILLE, Calif., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced today that it has learned that Osmotica Pharmaceuticals LLC and Vertical Pharmaceuticals LCC (Osmotica) filed an action in Delaware federal court on February 16, 2018 requesting a declaratory judgment that Osmotica’s newly-approved product OSMOLEX ER™ (amantadine) extended-release tablets does not infringe certain of Adamas’ patents. Adamas has not received service of a summons and complaint. The complaint does not allege patent infringement against Adamas or otherwise pertain to Adamas’ product GOCOVRI™ (amantadine) extended release capsules. OSMOLEX ER was approved by the U.S. Food and Drug Administration (FDA) on February 16, 2018 for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients, indications approved for immediate release amantadine in 1972. As Osmotica states in the complaint, drug-induced extrapyramidal reaction is a sep
Show less
Read more
Impact Snapshot
Event Time:
ADMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADMS alerts
High impacting Adamas Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics